Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563793 · ClinicalTrials.gov registry record
Postmarket Outcomes Study for Evaluation of the Superion™ Spacer
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 129
- Enrollment target
NCT04563793: Completed study, sponsored by Boston Scientific Corporation.
NCT04563793 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04563793 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 129 participants
- Enrollment target
Study Summary
To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
Primary Outcome
Proportion of subjects with an improvement of 20 mm during the last 7 days for low back pain at 6 months, 1 year, 2 years, and 3 years post-procedure compared with Baseline (VAS)
Interventions
- DEVICE Superion™ IDS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2023-03-20 |
What the finished NCT04563793 record still lists
NCT04563793 is an observational study that tracks outcomes without assigning an intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Superion™ IDS is the first listed.
NCT04563793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04563793 about?
NCT04563793 is a clinical study titled "Postmarket Outcomes Study for Evaluation of the Superion™ Spacer". To compile real-world outcomes of the Superion™ IDS in routine clinical practice.
What is the current status of trial NCT04563793?
This trial is currently completed. The enrollment target is 129 participants. The study started on 2020-10-08. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT04563793?
The interventions under investigation include: Superion™ IDS (DEVICE).
Who is sponsoring clinical trial NCT04563793?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI